This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Oral GLP-1s Won’t Win on Convenience – They’ll Win on CMC
GLP-1 peptides validated the science. CMC will validate the small molecule modality for GLP-1 efficacy, scalability, and access.
